Abstract 1872: Pharmacological inhibition of WIP1 sensitizes AML cells to MDM2 inhibitors
Maria Chiara Fontana(Istituto Oncologico Romagnolo), Giovanni Martinelli(University of Bologna), Giovanni Marconi(University of Bologna), Jacopo Nanni(Istituto di Ematologia di Bologna), Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Giorgia Simonetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Antonella Padella(University of Bologna), Michèle Cavo(Unknown), Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Samantha Bruno(University of Bologna), Mariachiara Abbenante(University of Bologna)
Cited by 0
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k